RxDoctor Payments Data

Stephen Kelly, MD

Ophthalmology · Birmingham, ALNPI 1205059169

Payments from drug & device makers

$2,718in general payments, 2019–2025

Across 73 payments — averaging $37.23 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Alcon$2K
  • AbbVie$376
  • Sun Pharmaceutical Industries Inc.$209
  • Aerie Pharmaceuticals, Inc.$117
  • Bausch & Lomb Americas Inc.$111
  • Thea Pharma Inc.$86
  • plus $299 from 10 others

What the payments were for

  • Food & beverage$2,718100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$2,718 in reported general payments places this provider in the 60th percentile of 197 ophthalmology providers in Alabama.

See all ophthalmology providers in Alabama

Medicare billing

Part B allowed, 2024
$219,674
Medicare patients
928
Services billed
1,763

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
RestasisCyclosporine112$114,399
XiidraLifitegrast16$24,785
LumiganBimatoprost45$16,723
Cyclosporine22$15,693
MoxifloxacinMoxifloxacin Hcl369$12,872
Prednisolone Acetate333$10,762
MieboPerfluorohexyloctane/Pf13$9,849
Ketorolac Tromethamine323$6,218
Travoprost26$4,979
Latanoprost231$4,504
Brimonidine Tartrate25$4,297
ValacyclovirValacyclovir Hcl20$2,400
Timolol Maleate109$2,399
Dorzolamide-TimololDorzolamide Hcl/Timolol Maleat71$1,664
Neomycin-Polymyxin-DexamethNeomycin/Polymyxin B/Dexametha88$1,293

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AbbVieRestasis, Lumigan$376$131,122157 claims
Bausch & Lomb Americas Inc.Xiidra, Miebo$111$34,63429 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 60th percentile of 197 ophthalmology providers in Alabama.

Other ophthalmology in Birmingham

See the full list for Alabama

Where these figures come from

Is this you, or does something look wrong? →